Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer

Shuyan Sheng, Zhaozhen Wu, Hua Zheng, Hui Zhang, Quan Zhang, Zan Liu, Shouzheng Wang, Xi Li, Jie Li, Jialin Lv, Ying Hu Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, People’s R...

Full description

Saved in:
Bibliographic Details
Main Authors: Sheng S, Wu Z, Zheng H, Zhang H, Zhang Q, Liu Z, Wang S, Li X, Li J, Lv J, Hu Y
Format: Article
Language:English
Published: Dove Medical Press 2025-07-01
Series:Journal of Inflammation Research
Subjects:
Online Access:https://www.dovepress.com/prognostic-value-of-c-reactive-protein-to-lymphocyte-ratio-in-combined-peer-reviewed-fulltext-article-JIR
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849423481571115008
author Sheng S
Wu Z
Zheng H
Zhang H
Zhang Q
Liu Z
Wang S
Li X
Li J
Lv J
Hu Y
author_facet Sheng S
Wu Z
Zheng H
Zhang H
Zhang Q
Liu Z
Wang S
Li X
Li J
Lv J
Hu Y
author_sort Sheng S
collection DOAJ
description Shuyan Sheng, Zhaozhen Wu, Hua Zheng, Hui Zhang, Quan Zhang, Zan Liu, Shouzheng Wang, Xi Li, Jie Li, Jialin Lv, Ying Hu Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of ChinaCorrespondence: Ying Hu, Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China, Email huying@bjxkyy.cnPurpose: Inflammatory indexes are emerging as sensible prognostic factors for small cell lung cancer (SCLC). However, the prognostic value of dynamic C-reactive protein-to-lymphocyte ratio (CLR) in SCLC patients treated with chemoimmunotherapy remains unclear.Patients and Methods: This retrospective study investigated 88 SCLC patients who underwent chemoimmunotherapy between January 1st, 2020 and December 12th 2022. We examined the association between CLR and prognostic outcomes after chemoimmunotherapy. The associations between objective response rate (ORR), progression-free survival (PFS) with changes in blood indicators were also analyzed.Results: Patients with decreased CLR had significantly higher ORR, with odds ratios of 3.91 (P< 0.05) and 3.19 (P< 0.05) in univariate and multivariate logistic regression analyses, respectively. Kaplan-Meier analysis showed that decreased CLR was associated with prolonged PFS (P=0.02). Additionally, a CLR higher than 2.47 after treatment was associated with poor survival in both univariate and multivariate analyses.Conclusion: Dynamic CLR can serve as a potential biomarker for predicting the prognosis of SCLC patients treated with chemoimmunotherapy. Reduction of CLR after chemoimmunotherapy is associated with a significantly higher ORR and improved PFS.Keywords: small cell lung cancer, chemoimmunotherapy, C-reactive protein-to-lymphocyte ratio
format Article
id doaj-art-a9731a7cf8744dc2bb3e8d2f447e52bf
institution Kabale University
issn 1178-7031
language English
publishDate 2025-07-01
publisher Dove Medical Press
record_format Article
series Journal of Inflammation Research
spelling doaj-art-a9731a7cf8744dc2bb3e8d2f447e52bf2025-08-20T03:30:33ZengDove Medical PressJournal of Inflammation Research1178-70312025-07-01Volume 18Issue 193439353104897Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung CancerSheng S0Wu Z1Zheng H2Zhang H3Zhang Q4Liu Z5Wang S6Li X7Li J8Lv J9Hu Y10Department of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyShuyan Sheng, Zhaozhen Wu, Hua Zheng, Hui Zhang, Quan Zhang, Zan Liu, Shouzheng Wang, Xi Li, Jie Li, Jialin Lv, Ying Hu Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of ChinaCorrespondence: Ying Hu, Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China, Email huying@bjxkyy.cnPurpose: Inflammatory indexes are emerging as sensible prognostic factors for small cell lung cancer (SCLC). However, the prognostic value of dynamic C-reactive protein-to-lymphocyte ratio (CLR) in SCLC patients treated with chemoimmunotherapy remains unclear.Patients and Methods: This retrospective study investigated 88 SCLC patients who underwent chemoimmunotherapy between January 1st, 2020 and December 12th 2022. We examined the association between CLR and prognostic outcomes after chemoimmunotherapy. The associations between objective response rate (ORR), progression-free survival (PFS) with changes in blood indicators were also analyzed.Results: Patients with decreased CLR had significantly higher ORR, with odds ratios of 3.91 (P< 0.05) and 3.19 (P< 0.05) in univariate and multivariate logistic regression analyses, respectively. Kaplan-Meier analysis showed that decreased CLR was associated with prolonged PFS (P=0.02). Additionally, a CLR higher than 2.47 after treatment was associated with poor survival in both univariate and multivariate analyses.Conclusion: Dynamic CLR can serve as a potential biomarker for predicting the prognosis of SCLC patients treated with chemoimmunotherapy. Reduction of CLR after chemoimmunotherapy is associated with a significantly higher ORR and improved PFS.Keywords: small cell lung cancer, chemoimmunotherapy, C-reactive protein-to-lymphocyte ratiohttps://www.dovepress.com/prognostic-value-of-c-reactive-protein-to-lymphocyte-ratio-in-combined-peer-reviewed-fulltext-article-JIRSmall cell lung cancerchemoimmunotherapyC-reactive protein-to-lymphocyte ratio
spellingShingle Sheng S
Wu Z
Zheng H
Zhang H
Zhang Q
Liu Z
Wang S
Li X
Li J
Lv J
Hu Y
Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer
Journal of Inflammation Research
Small cell lung cancer
chemoimmunotherapy
C-reactive protein-to-lymphocyte ratio
title Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer
title_full Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer
title_fullStr Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer
title_full_unstemmed Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer
title_short Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer
title_sort prognostic value of c reactive protein to lymphocyte ratio in combined immunotherapy and chemotherapy for small cell lung cancer
topic Small cell lung cancer
chemoimmunotherapy
C-reactive protein-to-lymphocyte ratio
url https://www.dovepress.com/prognostic-value-of-c-reactive-protein-to-lymphocyte-ratio-in-combined-peer-reviewed-fulltext-article-JIR
work_keys_str_mv AT shengs prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer
AT wuz prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer
AT zhengh prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer
AT zhangh prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer
AT zhangq prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer
AT liuz prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer
AT wangs prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer
AT lix prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer
AT lij prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer
AT lvj prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer
AT huy prognosticvalueofcreactiveproteintolymphocyteratioincombinedimmunotherapyandchemotherapyforsmallcelllungcancer